The androgen receptor (AR) is expressed in many cell types and the androgen/AR signaling has been found to have important roles in modulating tumorigenesis and metastasis in several cancers including prostate, bladder, kidney, lung, breast and liver. However, whether AR has differential roles in the individual cells within these tumors that contain a variety of cell types remains unclear. Generation of AR knockout (ARKO) mouse models with deletion of AR in selective cells within tumors indeed have uncovered many unique AR roles in the individual cell types during cancer development and progression. This review will discuss the results obtained from various ARKO mice and different human cell lines with special attention to the cell type-and tissue-specific ARKO models. The understanding of various results showing the AR indeed has distinct and contrasting roles in each cell type within many hormone-related tumors (as stimulator in bladder, kidney and lung metastases vs as suppressor in prostate and liver metastases) may eventually help us to develop better therapeutic approaches by targeting the AR or its downstream signaling in individual cell types to better battle these hormone-related tumors in different stages.
INTRODUCTION
Androgen/androgen receptor (AR) signaling has an important role in initiation and progression of many hormone-related cancers. In most cases, AR triggers its action through binding with testosterone/5a-dihydrotestosterone (DHT), which leads to the AR conformational change and its translocation from the cytosol to the nucleus to elicit transcriptional regulation of target genes that can be further modulated by various AR coregulators. [1] [2] [3] However, the AR can also be activated through non-liganddependent pathways and androgen/AR signaling can be activated by interacting with other proteins and exert its non-genomic function. 4, 5 In the past few decades, most AR in vivo studies involved surgical castration to reveal the role of androgen/AR signaling in cancer development and progression. Successful generation of AR knockout (ARKO) mouse models with AR deleted in selective cell types 6 has provided a powerful approach to study the role of androgen/AR signaling in a variety of cancers.
This review will summarize recent in vivo results obtained from various ARKO mouse models (Table 1 ) and a few cases of AR knock-in models. The possible impacts of androgen/AR signaling on various cancers will be discussed, and understanding these impacts may help us to develop unique AR target(s) in selective cells for therapeutic approaches in the future to better battle cancers.
AR PATHOPHYSIOLOGICAL ROLES IN PROSTATE CANCER
The AR has both stimulator and suppressor roles in different prostate cancer (PCa) cell types during PCa progression and metastasis. 7 This viewpoint is based on the results of several clinical observations and in vivo studies using different mouse models with AR being knocked-out and knocked-in in different PCa cell types. Here we will briefly summarize the results of these observations.
Increasing AR activity in prostatic epithelial cells can promote PCa initiation Han et al. 8 generated transgenic mice with prostate epitheliumspecific ectopic expression of the wild-type mouse AR (mAR, Wt), mAR(T857A) (equivalent to hAR(T877A)) or AR(E231G) driven by the minimal probasin promoter mice. Transgenic mice expressing AR(E231G), but not mAR(T857A) or mAR, developed prostatic intraepithelial neoplasm (PIN) at 12 weeks and formed invasive PCa at 50 weeks of age. As AR(E231G) is constitutively active, it appeared that increasing the prostatic epithelial AR activity with AR(E231G), but not ligand responsive AR(T857A), can promote PCa initiation. Thus, we may also observe PCa initiation in the transgenic mice expressing other consitutively active AR mutants than AR(E231G) that have been found in PCa. However, it should be noted that AR mutations are not generally observed in human primary PCa. Therefore, it will be interesting and more pathophysiologically relevant to determine if such constitutively active AR mutation is involved in PCa relapse after androgen deprivation therapy (ADT).
Zhu et al. 9 reported the generation of a conditional human AR (hAR) transgene knock-in mouse model (hARKI mouse) using Cre-loxP recombination technology in which a loxp-stop-loxp cassette was inserted between a cytomegalovirus (CMV) enhancer/chicken b-actin promoter (CAG promoter) and hAR coding sequence. After mating mice carrying the floxed transgene 1 with Cre mice, the excision of the loxp-stop-loxp cassette would permit the CAG promoter-driven expression of hAR transgene driven by the CAG promoter. The hARKI(Osr1-Cre) mice were generated by crossing the hAR-floxed mice with mice carrying the odd-skipped related 1 promoter-driven Cre (Osr1-Cre), which becomes active in urogenital sinus epithelium at E11.5 and maintained activity in prostatic epithelium throughout development. The hAR transgene was expressed in both basal and luminal epithelial cells in hARKI(Osr1-Cre) mice. In contrast, crossing the hAR-floxed mice with probasin-Cre mice resulted in expression of the hAR transgene mainly in prostatic luminal epithelial cells of hARKI(probasin-Cre) mice. About 50% of hARKI(Osr1-Cre) mice developed PIN at 8 weeks and 10% developed prostatic adenocarcinoma at 8 to 21 months of age; whereas prostates of hARKI(probasin-Cre) mice developed only PIN. All atypical epithelial cells in PIN and adenocarcinoma expressed the hAR with increased cell proliferation. These results indicate that increasing AR activity either by AR gene mutation or overexpression in prostate epithelial cells would promote PCa initiation, although the underlying mechanisms remain unclear.
AR in PCa stromal cells: a stimulator for tumor initiation and progression As in the normal prostate, the stromal-epithelial interaction remains important for tumor progression and metastasis. Tumor stromal cells including fibroblasts, myofibroblasts, endothelial and immune cells, form a microenvironment to support the progression and metastasis of the tumor. In normal human prostate, the stroma consists mainly of smooth muscle cells expressing the AR, whereas the tumor stroma is constituted mainly of fibroblastic and myofibroblastic cells, suggesting that cell-transition changes have occurred in both the stroma and the epithelium during tumorigenesis.
AR-negative epithelial PC-3 cells co-cultured with human prostatic stromal WPMY1-v or WPMY-AR-si cells indicated that knock-down of AR in WPMY1-ARsi cells resulted in the co-cultured PC-3 cells being less invasive in an in vitro invasion assay than PC-3 cells with vector-transfected WPMY1-v cells. 10 After orthotopic inoculation in nude mice, PC-3 cells also produced smaller primary and pelvic lymph node (PLN) metastatic tumors when combined with WPMY1-ARsi than with WPMY1-v cells. 10 Similar in vivo androgen/AR-dependent tumor growths were also observed using other PCa cell lines, 11, 12 and LNCaP cells grew more aggressively on orthotopic transplantation after being co-inoculated with rat urogenital sinus mesenchyme (UGM) or bone marrow fibroblasts. 13 Male Pten þ / À mice develop PIN lesions that progress from low to high grades. 14 Lai et al. 15 have generated a fibromuscular ARKO (fibroblast and smooth muscle double-specific ARKO, Fsp-ARKO/ SM-ARKO) model of the Pten Liver cancer ARKO ACTB-Cre All cell types except RBCs
Reduced tumor incidence in both male and female DEN-induced liver cancer model. 43 Hep-ARKO Albumin-Cre Hepatocytes Reduced tumor incidence at young age but had enhanced tumor progression and metastasis leading to lower survival rate in both male and female DEN-induced liver cancer models. 43, 94 Hep-ARKO/HBV Albumin-Cre Hepatocytes Decreased hepatocellular carcinoma incidence, tumor volume, number tumor foci and development of premalignant lesions compared with HBV mice.
100
Lung cancer Ind-ARKO Mx1-Cre All cell types Induction of ARKO in male mice decreased tumor incidence in the chemical carcinogen NNK-BaP-induced lung cancer model compared with uninduced and floxed AR control mice. 74 
Breast cancer AR -Ex3
CMV-Cre Most cell types if not all.
Accelerated DMBA-induced mammary carcinogenesis in female knockout mice. Nipple development in male knockout mice. 82 
AR -EX3
Sox2-Cre All cell types Accelerated DMBA-induced mammary carcinogenesis in female knockout mice. 17 Similarly, tissue recombination of mouse UGM with human prostate epithelial cell lines, BPH-1 or RWPE-1, in intact nude mice treated with testosterone þ estradiol (E2) resulted in formation of invasive tumors and metastasis. 17, 18 Co-transplantation of prostate epithelial cells of Pten þ / À /Trp53 þ / À mice, BPH-1 or RWPE-1 with UGM of Tfm mice led to formation of small benign prostate tissues without metastasis. In contrast, recombination of Wt mouse UGM and AR knocked-out BPH-1cells (using AR-short hairpin RNA), resulted in large tumors and metastases. Primary epithelial cells isolated from recombinant tumors derived from BPH-1 or AR knocked-out BPH-1 cells were found to form invasive tumors capable of metastasis without needing co-transplantation with AR-positive stromal cells, indicating that they had already gone through malignant transformation. 17 These observations might suggest that the stromal AR, not the epithelial AR, may have key roles for malignant transformation of prostate epithelial cells.
Interestingly, Olapade-Olaopa et al. 19 showed that malignant transformation of human prostatic epithelium is associated with the loss of AR immunoreactivity in the surrounding stroma and Li et al. 20 reported that decrease in stromal AR level is associated with PCa cells invasion. The detailed mechanisms for these contrasting results, however, remain unclear and more studies are needed before we can draw final conclusions about stromal AR role in human PCa metastasis.
AR in PCa epithelial cells: an anti-apoptotic survival factor in CK8-positive luminal epithelial cells and a suppressor of proliferation in CK5/CK8-positive intermediate cells The transgenic adenocarcinoma of the mouse prostate (TRAMP) mouse model is a PCa model generated by introducing rat probasin promoter-driven SV40 T antigen (PB-Tag) in which PCa develops spontaneously. 21 In TRAMP mice, the PB-Tag transgene is spatially restricted to dorso-lateral and ventral prostate lobes and is expressed heterogeneously in prostatic epithelium in young mice and becomes uniformly expressed in adult mice. TRAMP mice develop epithelial hyperplasia between 10 and 12 weeks of age, and at 18 weeks old or older develop invasive adenocarcinoma that metastasizes to lymph nodes, lung, and occasionally to kidney, adrenal glands and bone. 22 TRAMP mice were mated with the exon 2-floxed AR mice 6 to obtain AR floxed-TRAMP mice, which in turn were crossed with the probasin-Cre mice 23 to generate prostate epithelial-specific (pes)-ARKO/TRAMP mice. 10, 24 However, it should be noted that the SV40 T antigenderived prostate tumors in TRAMP mice may not represent real human cases. For example, these mice showed a much higher number of neuroendocrine tumors, 25 which is not consistent with human patients cases. Therefore, careful interpretations of data obtained from TRAMP mice studies will be needed to draw appropriate conclusions.
Prostatic epithelial cells develop from stem cells via proliferation and differentiation stepwise into basal and intermediate cells, and finally into luminal epithelial cells. 26, 27 AR is expressed in some basal cells and all of the luminal cells in mouse prostate. 28, 29 Similar to pes-ARKO mice, 30 knocking out AR from these epithelial cells in pes-ARKO/TRAMP mice resulted in increased apoptosis of CK8-positive luminal epithelial cells (18%) as compared with those (2%) found in Wt TRAMP mice, 28 suggesting that the AR in luminal epithelial cells may function as a survival factor to protect PCa cells from apoptosis.
However, ablation of the epithelial AR in pes-ARKO/TRAMP mice also resulted in increasing numbers of proliferating CK5-positive basal cells, including the CK5/CK8 double-positive intermediate cells. Consequently, the increased luminal epithelial cells apoptosis and increased basal intermediate cells proliferation then resulted in less differentiated yet larger primary tumors in the ventral prostate of pes-ARKO/TRAMP mice than tumors from TRAMP mice at the same age. 24 Importantly, CD44-positive stem/ progenitor PCa cells sorted from human PCa xenografts were highly tumorigenic and metastatic. 31 Thus, the loss of the epithelial AR that led to cell population changes with expansion of CD44-positive stem/progenitor and CK5-positive intermediatelike tumor cells and decrease of secretory CK8-positive luminal tumor cells in the prostates of pes-ARKO/TRAMP mice might result in the increase in PCa progression/invasion. 10 These results suggested that the epithelial AR might function as a proliferation suppressor in CK5/CK8 double positive cells and a survival factor in CK8 þ luminal epithelial cells. As prostate tumors arise mainly from epithelial cells, the opposite functions of the epithelial AR in different types of epithelial cells could then affect PCa progression in TRAMP mice at different stages with different effects (see next two sections).
The suppressor function of the epithelial AR was also demonstrated in various PCa cell lines. Reducing AR expression by AR-siRNA in various PCa cells promoted orthotopically transplanted PCa metastasis, whereas ectopic expression of the AR in PCa cells suppresses the metastasis of their orthotopic xenograft tumors. 7 The presence of the AR in prostate stem/progenitor cells is controversial, but it is generally accepted that the mRNA level of AR is low, and its protein expression level is almost nondetectable. 26, 32, 33 Lee et al. 34 found little AR protein in CD133
þ PCa stem/progenitor cells. Tian et al. 35 also found very low levels of AR in normal mouse prostate stem/progenitor cells and various PCa stem/progenitor cells, and these very low levels of AR can be due to dense methylation of their AR promoters. Methylation of AR promoters has been shown to suppress AR transcription. 36 Treating murine prostatic stem/progenitor and various PCa stem/ progenitor cells with 5-aza-2 0 -deoxycytidine resulted in decreased AR promoter methylation and expression of various stemness markers, increased AR expression and various prostate epithelial cell differentiation markers, and suppression of their proliferation. Moreover, the human PCa stem/progenitor cells treated with 5-aza-2 0 -deoxycytidine and then transplanted orthotopically into 5-aza-2 0 -deoxycytidine-treated immunodifficient mice produced smaller xenograft tumors than the untreated cells in vehicletreated host. 35 These observations also support the notion that the AR in PCa stem/progenitor cells functions as a tumor suppressor.
AR in PCa epithelial cells: a suppressor of PCa metastasis
The AR in PCa epithelial cells also has a suppressor role in tumor metastasis. Thus, at 24 weeks old, pes-ARKO/TRAMP mice produced larger PLN metastatic tumors and developed more metastatic foci in the liver than Wt TRAMP mice. 10 In addition, ARnegative PLN metastatic tumor cells isolated from pes-ARKO/ TRAMP mice were more invasive in vitro and produced larger xenograft tumors than AR-positive tumor cells isolated from TRAMP mice. The invasive property of PLN tumor cells from pes-ARKO/TRAMP mice was reduced by ectopic expression of a functional AR via transfection. 10 Gingrich et al. 21 also found that Learning AR roles in cancers via ARKO mice C Chang et al castrated TRAMP mice developed more aggressive PLN metastatic tumors than intact TRAMP mice. Therefore, it may be concluded that, in mice, the epithelial AR also functions as a suppressor of PCa invasion and metastasis.
Targeting PCa epithelial and stromal AR at different stages results in differential effects on PCa progression and metastasis The ind-ARKO/TRAMP 24 mice were generated to assess the consequence of simultaneous knockdown of both the epithelial and stromal AR that have opposite roles in PCa progression and metastasis. The ARKO in ind-ARKO/TRAMP mice is mediated by Mx1-Cre, which is interferon inducible and can be activated by injection of polyinosinic-polycytidic acid (pI-pC) to induce endogenous interferon expression and thus activate the Cre recombinase in various tissues 37 including the prostate. 24, 38 After injection of pI-pC at 12 weeks old, AR mRNA expression in the prostate was found knocked down by 50% in the stroma and 60% in the epithelium in 16 weeks old ind-ARKO/TRAMP mice compared with pI-pC-injected control TRAMP mice. Knocking down prostatic AR expression in both stromal and epithelial cells at this early stage resulted in smaller and less differentiated primary prostate tumors in ind-ARKO/TRAMP than in the control TRAMP mice through 16 to 24 weeks old, suggesting the positive stimulator roles of the stromal AR are more dominant than the negative suppressor roles of the epithelial AR in early stage PCa. 24 Metastatic tumors were also compared among Wt TRAMP, pes-ARKO/TRAMP and ind-ARKO/TRAMP mice at different ages, and results showed the poorly differentiated tumors of pes-ARKO/ TRAMP mice developed the largest PLN metastatic tumors and metastasized into multiple organs, whereas those of ind-ARKO/ TRAMP mice were smallest and they metastasized into the seminal vesicles and liver. Thus, loss of the epithelial AR promotes PCa progression and metastasis as shown in pes-ARKO/TRAMP, whereas concurrent knockdown of the stromal and epithelial AR at an early stage can override these effects of the epithelial ARKO, thereby retarding growth of the tumors and suppressing their metastasis as shown in ind-ARKO/TRAMP mice.
More importantly, ind-ARKO/TRAMP mice with early knockdown of prostatic AR had longer survival time than Wt TRAMP and pes-ARKO/TRAMP mice. 24 However, the dominance of the stromal AR over the epithelial AR function diminished when ARKO was induced after the primary tumor had progressed over an extended time period. When ARKO was induced in 20 weeks old ind-ARKO/TRAMP mice, the sizes of primary and PLN metastatic tumors developed after 24 weeks of age were similar between ind-ARKO/TRAMP and TRAMP mice, suggesting the relative influences of the stromal vs epithelial AR signals on PCa progression and metastasis can vary with the progression of the tumor, depending on when the AR gene is knocked out. 24 Together, these observations not only support the notion that the epithelial AR functions as a tumor suppressor for PCa progression/metastasis, but also indicate that the stromal AR may function as a stimulator of the PCa progression/metastasis, especially at an early stage.
Differential AR roles in different human PCa cell types The differential AR roles in different PCa cells seen in ARKO mouse models were also observed in the human prostate tumors. Immunohistochemical analyses of human PCa 39 indicated that the CK5/CK8-positive intermediate cells, which have high metastatic potentials, 40 increased from 29% without ADT to 75% with ADT. Moreover, three primary PCa cell lines isolated from the same PCa patient exhibited differential growth responses when transplanted orthotopically in castrated SCID mice with and without androgen supplementation. 7 One line grew more rapidly, whereas another line grew more slowly, in castrated than androgen-supplemented mice, suggesting that they are androgen-suppressed vs androgenstimulated PCa cells. In contrast, the third line grew at the same rate in hosts with or without androgen supplementation and thus was androgen insensitive, 7 suggesting that differential androgen/ AR signaling could exist in the tumors of each individual PCa patient, and this might be the reason why the current ADT that reduces/prevents androgens from binding to the AR in every cell might fail.
Furthermore, a recent study of PCa tissues obtained from seven patients before and after ADT have indicated that ADT resulted in tumor cell population changes. 41 Before ADT, the tumors contain higher populations of AR-expressing non-stem/progenitor cells and lower levels of AR-deficient stem/progenitor cells. After ADT, non-stem/progenitor cell populations decreased while stem/ progenitor cell populations increased. Similar cell population changes were observed in the xenografted tumors of LNCaP and C4-2 PCa cells after castration of the host. Most importantly, combination treatment of nude mice hosts orthotopically transplanted with various castration-resistant human PCa cell lines using an AR degradation enhancer, ASC-J9, [42] [43] [44] together with combination of g-tocotrienol and 5-aza-2 0 -deoxycytidine (both suppressed stem/progenitor cell proliferation) resulted in significant reduction in tumor size and tumor cell proliferation indices compared with tumors in vehicle-treated hosts. 41 In summary, the clinical studies appear to support the notion that the AR has differential pathophysiological roles in PCa progression and metastasis in different cells as deduced from studies with various PCa mouse models with ARKO, human PCa cell xenografts and PCa patients.
AR PATHOPHYSIOLOGICAL ROLES IN BLADDER CANCER AND UPPER URINARY TRACT UROTHELIAL CARCINOMA (UUTUC)
In humans, males have a substantially higher risk of developing bladder cancer (BCa) than females. 45, 46 In animal experimental models, males are more likely than females to develop BCa induced by certain chemical carcinogens such as N-butyl-N-(4-hydroxybutyl)nitrosamine (BBN). 47 In men, the AR is a potential mediator of sex-related predominance in BCa incidence. The AR has been detected in normal bladder epithelium of male rat 48 and in BCa from both male and female patients. 49 Knocking out AR in ARKO mice suppresses BCa development Miyamoto et al. 50 studied the AR roles in BCa progression by comparing the development of BBN-induced BCa in male and female AR total knockout mice, ARKO(ACTB-Cre), and their Wt littermates, and by studying the effect of AR ablation on the progression of human BCa cell xenografts. In each group of 12 animals examined, invasive BCa developed in 92% of the BBNtreated Wt male mice at 40 weeks of age, whereas only 42% of BBN-treated Wt female mice at the same age had developed BCa, 50 confirming the sexual dimorphic incidence of BBN-induced BCa. 48 Importantly, BBN did not induce BCa in male or female ARKO(ACTB-Cre) mice at 40 weeks, suggesting that the AR has a key role to promote bladder carcinogenesis.
Interestingly, castration in Wt male mice only reduced BCa incidence to 50%. These contrasting results (castrated Wt male mice having little androgen but still with AR expression vs ARKO mice having little androgen without AR expression) indicated that the AR expressed in castrated Wt mice might still be able to function through some non-androgen-mediated pathways to promote bladder carcinogenesis. Furthermore, 25% ARKO(ACTBCre) male mice supplemented with DHT developed bladder carcinomas, suggesting DHT in ARKO(ACTB-Cre) male mice might be able to function through non-AR pathways to induce bladder carcinogenesis.
These results suggest that androgen/AR signaling can either function through classic androgen/AR pathways or androgen/ non-AR pathways or non-androgen/AR pathways to influence BCa development and progression.
Izumi et al. 51 observed that the expression levels of UDPglucuronosyltransferase subtypes (UGTs), which have an important role in BCa initiation by detoxifying carcinogens, were elevated in bladders of ARKO(ACTB-Cre) and castrated Wt mice and the levels of bladder UGTs in castrated Wt mice were reduced by treatment with DHT. Histochemical staining levels of UGT1A in BCa tissues (46%) were reduced compared with the corresponding benign tissues (94%). These observations strongly suggested that androgen/AR signaling could promote BCa initiation by downregulating the expression levels of UGTs.
The growth of subcutaneous xenografts of a human BCa cell line expressing a functional AR were suppressed by treatment of the host with castration, the anti-androgen, hydroxyflutamide, or the AR degradation enhancer, ASC-J9. 44 These treatments resulted in significant decreases in tumor proliferation indices, and increases in apoptosis indices. These treatments also resulted in decreased expression levels of angiogenesis-and metastasisrelated factors, including basic fibroblast growth factor, vascular endothelial growth factor and matrix metalloproteinase-9. After knock-down of the endogenous AR by stable transfection with ARsiRNA, formation of xenograft tumors from two AR-positive BCa cell lines were delayed compared with the control cell lines. 50 These observations not only support the notion that the AR has important roles in bladder carcinogenesis and cancer progression, but also indicate that treatment of BCa by targeting the AR directly with AR-siRNA or ASC-J9 might be effective.
Loss of AR in urothelial cells suppresses BCa development
The role of the urothelial AR in BCa was further studied by knocking out the AR specifically in the urothelium. Male urothelium-specific ARKO (Uro-ARKO) mice were generated 52 by crossing male uroplakin II promoter-driven Cre (UPII-Cre) mice 53 with female heterozygous exon 2-floxed AR mice. 6 Similar to ARKO(ACTB-Cre) mice, Uro-ARKO mice had lower incidence of BCa than their Wt littermates after induction with BBN, suggesting a positive urothelial AR role in BCa development.
The bladder tumors of Wt mice exhibited higher proliferation index and lower apoptosis index than the tumors in Uro-ARKO mice. 52 In addition, the urothelium of Uro-ARKO in comparison with Wt mice displayed lower extent of DNA damage that was associated with elevated expression of p53 (a tumor suppressor) and proliferating cell nuclear antigen (a key player in DNA excision repair upregulated by p53). 52 Mice harboring SV40 large T antigen in the urothelium (SV40T mice carrying UPII-SV40T transgene) develop spontaneous BCa because of inactivation of p53. 54 Male SV40T mice carrying UPII-Cre (after mating with UPII-Cre mice) were crossed with female heterozygous exon 2-floxed AR mice to generate male SV40T/Uro-ARKO mice and SV40T mice carrying Wt AR. However, there was no difference in BCa incidence between SV40T and SV40T-Uro-ARKO mice, suggesting that the urothelial AR is unable to promote tumor formation without p53. 52 This conclusion was further supported by bladder cell transformation assays showing that adding p53 inhibitor led to little difference in neoplastic transformation between SV-HUC-1 cells stably transfected with either AR-cDNA or vector control. 52 These observations indicate that the urothelial AR promotes bladder tumorigenesis and progression via a p53-dependent pathway.
AR expression in UUTUC cancer
In addition to BCa, urothelial cells may also develop another tumor, UUTUC, which accounts for approximately 5-10% of all urothelial tumors. 55 Patients with UUTUCs with invasion into the muscle wall usually have a very poor prognosis with 5-year survival rate o50% for pT2/pT3 and o10% for pT4. 55, 56 The median survival of 7-9 months was shown in pT4 patients even with radical nephroureterectomy and chemotherapy. 56, 57 UUTUC is a male-dominant disease with the male to female ratio: 2:1 to 2.5:1. 58, 59 Survival of UUTUC patients was significantly influenced by the male gender, 60 and sex and stage of UUTUC patients were the only independent prognostic factors predictive of overall survival and the female gender was associated with a better survival. 60 These studies suggest that sex hormones may have important roles in affecting the development and progression of UUTUC.
Recent studies have suggested that a positive correlation with higher AR expression is associated with superficial or low-grade UUTUCs of ureter in clinical specimens. 61 Immunohistochemistry from 43 primary urothelial tumors of renal pelvis and 40 primary urothelial tumors of ureter revealed that the AR was positive in 55% of UUTUC patients. 61 Interestingly, their results also found that AR expression was decreased in tumors with increased pathologic stage and high grades, suggesting that AR expression may be associated with UUTUC progression and invasion.
AR roles in migration/invasion of UUTUC cells and its linkage to chemotherapy UUTUC patients with locally advanced and poorly differentiated tumors may have a poorer outcome since they may experience disease recurrence and subsequently die from metastatic UUTUC. 57, 62 Chen et al. 63 found that addition of functional AR into UUTUC transformed cell lines, SV-HUC and BFTC 909, led to increased cell migration and invasion that might be mediated by the upregulation of the metastasis-related genes, matrix metalloproteinase-9, Rock-1 and Cox 2 by the AR. Targeting the AR with ASC-J9, in the UUTUC BFTC 909 cells resulted in increased cell sensitivity to both chemotherapeuic agents, doxorubicin and mitomycin C. 63 Hsieh et al. 64 also found that addition of the AR in BFTC 909 cells increased cell viability on treatment with chemotherapeutic agents, cisplatin and doxorubicin, an effect that might be mediated through modulation of the membrane transporter protein ABCG2, a multi-drug chemoresistance factor in cancer cells. 65 Together, results from studies of AR roles in UUTUCs suggest that AR may be a new potential therapeutic target to battle UUTUCs in the future.
AR PATHOPHYSIOLOGICAL ROLES IN KIDNEY CANCER
Renal cell carcinoma (RCC) accounts for near 2% of all adult malignancies and accounts for 80-85% of all kidney cancers. 66 Surgery remains the only effective treatment for RCC as metastatic disease is usually resistant to radiotherapy and chemotherapy, and has limited response rates of 10 to 20% to immunotherapy. 67 The epidemiology study indicates that RCC has a gender difference in tumor incidence (male-to-female ratio 1.6:1). 68 However, human RCC is not generally considered as a sex hormones-dependent tumor, despite immunohistochemistry studies indicating the AR expression might be linked to RCC development by showing higher AR expression in normal kidney tissues (90.9%) than in tumor tissues (30.0%, Po0.01). 69 Interestingly, the AR expression was found to be negatively associated with pT stage and Fuhrman's grade in RCC patients, yet the fact of little AR transactivation in RCC OSRC2 cells although the AR is expressed well in these RCC cells, suggesting assay AR expression alone might not be the best to conclude the AR roles in RCC progression. 69 Using three different RCC in vitro cell lines and two different RCC in vivo mouse models, Li et al. 69 found that targeting the AR via AR-siRNA or functional AR-cDNA resulted in altered RCC cell initiation, proliferation and invasion, suggesting AR might have positive roles in RCC development and progression. Mechanistic dissection further revealed that the AR might enhance RCC cell Learning AR roles in cancers via ARKO mice C Chang et al migration/invasion via modulation of vascular endothelial growth factor/hypoxia-inducible transcription factor 2 alpha (HIF-2a) signaling. Importantly, they found that targeting the AR with ASC-J9 treatment resulted in suppression of AR-induced HIF-2a/ vascular endothelial growth factor signaling. 69 These results suggested that AR might have important roles for RCC development and progression and targeting AR-induced HIF-2a/vascular endothelial growth factor signaling via ASC-J9 might become a potential new therapy to battle RCC in the future.
AR PATHOPHYSIOLOGICAL ROLES IN LUNG CANCER
Lung cancer is the leading cause of cancer mortality worldwide with unclear pathogenesis. The annual age-adjusted cancer incidence rates of lung cancer in males were higher than females in the United States. 70 It has been reported that the AR is expressed in human 71 and murine lung, mainly in type II pneumocytes and bronchial epithelium. 72 Androgen treatment increased AR expression and induced changes in gene expression profiles in murine lung and in the human adenocarcinoma cell line, A549. 72 Lu et al. 73 observed that the AR is overexpressed in the tumors of non-small cell lung cancer especially in the male patients. Knocking down the AR in non-small cell lung cancer cell lines using AR-siRNA lentivirus infection significantly suppressed cell proliferation and anchorage-independent growth in vitro through the downregulation of cyclin D1 expression. 73, 74 Non-small cell lung cancer cell lines with the AR knocked-down also displayed downregulation of Oct 4 protein expression. . 75 Induction of ARKO resulted in decrease in NNK-BaP-induced tumor incidence and reduced tumor size compared with control NNK-BaP mice carrying the floxed AR without Mx1-Cre. 74 These observations indicated that the AR in the lung might have important roles in promoting lung cancer development and progression.
AR PATHOPHYSIOLOGICAL ROLES IN BREAST CANCER
AR expression has been reported in over 70% of breast cancer and in 45-50% of patients with estrogen receptor alpha (ERa)-negative breast cancer. The tumor AR expression level was shown inversely associated with the 10-year survival of breast cancer patients. 76 However, AR expressions in these breast cancers are associated with better survival, despite stimulation of breast cancer cell proliferation by androgens in vitro. There are also increasing evidences indicating variable expression levels of the AR in ER/progesterone receptor double-negative and ER, progesterone receptor, and human epidermal growth factor receptor 2 (Her2) triple-negative breast cancer. 77, 78 It has been suggested that AR role in breast cancer is different depending on ERa expression. In ERa-positive luminal breast cancers, the AR has a growth inhibitor role, but conversely, AR signaling may promote growth of a subset of ERa-negative, AR-positive breast cancers. 79 However, there is a conflicting report suggesting that the androgen signaling pathway has a critical role in breast carcinogenesis, independent of the ER. 77 This AR expression and breast cancer survival paradox appears to be explained by a recent report that decreased AR expression in triple-negative breast cancer is associated with distant metastasis, 80 indicating the AR may function as a tumor suppressor. Androgen/AR-stimulated growth of the molecular apocrine breast cancer subtype via AR-regulated transcriptional program has been reported. 81 Ablation of the AR in human breast cancer epithelial cell line, MCF7, has been shown to suppress cell proliferation, 82 and the transfection of AR mutant-R608K, which is found in male breast tumors, into MCF7 cells led to increased mitogen-activated protein kinase activation that might contribute to the increased tumor incidence, 82 suggesting that AR might have a positive role to promote breast cancer progression. Thus, the AR appears to have differential functions acting either as a stimulator or suppressor of breast cancer progression, probably depending on the type of tumor. As both tumor stromal and epithelial cells express the AR, its cell-specific functions remain to be determined.
Recently, Simanainen et al. 83 studied the 7,12-dimethylbenz[a]anthracene (DMBA)-induced development of mammary tumors in AR exon 3 knocked out female mice, AR -EX3 (CMV-Cre) and AR -EX3 (Sox2-Cre), with different genetic backgrounds. They observed that DMBA-induced formation of mammary tumors in these female AR -EX3 mice were quicker than their corresponding CMV-Cre and Sox2-Cre Wt female mice and there was no difference because of genetic background. In contrast, DMBA failed to induce mammary tumor formation in male AR -EX3 or Wt mice except for the formation of local lymphoma without significant differences between the two genotypes. There was no difference in the expression levels of ERa and progesterone receptor in mammary glands of AR -EX3 and Wt female mice. They proposed that the AR genomic function is involved in suppressing mammary gland epithelial cell proliferation. As AR -EX3 males failed to develop mammary tumors, loss of AR genomic function alone does not promote DMBA-induced mammary gland carcinogenesis. It was suggested that DMBA-induced mammary carcinogenesis requires prior exposure of the gland to ovarian hormones and lacking AR genomic function would increase the sensitivity to this process. However, the expression of AR -zf2 protein in AR -EX3 female mice might have increased the AR non-genomic function, thereby rendering precise interpretation of these interesting observations difficult. Moreover, as female floxed AR mice were not compared in this study, it is uncertain whether any problem that was potentially inherited from the exon 3-floxed AR mice 84 might have contributed to the observed difference in AR -EX3 females. Therefore, additional studies, particular with mammary cell typespecific ARKO models, will be required to delineate the AR role(s) in mammary carcinogenesis.
AR PATHOPHYSIOLOGICAL ROLES IN LIVER CANCER
The incidence of hepatocellular carcinoma (HCC), regardless of etiology, is higher in males than females. 85 However, conflicting results have been reported for the link between the AR expression levels and prognosis of HCC. 86 Controversial results with castration in experimental HCC animal models [87] [88] [89] and clinical anti-androgen therapy [90] [91] [92] [93] have failed to establish the role of androgen/AR signaling in liver carcinogenesis and progression, suggesting the AR may also have differential roles, as observed in PCa, during development and metastasis of HCC as observed in PCa. A previous study in Tfm in comparison with Wt mice indicated that promotion of carcinogen-induced HCC formation by testosterone required a functional AR. 94 The availability of ARKO technology thus has provided valuable in vivo models to gain insights into the AR role(s) in HCC pathophysiology.
Loss of AR suppresses carcinogen-induced HCC development Ma et al.
43 generated male and female ARKO(ACTB-Cre) and hepatocyte-specific ARKO (Hep-ARKO) mice and compared N 0 -N 0 -diethylnitrosamine (DEN)-induced HCC development in these animals in comparison with their Wt littermates. In addition to gender differences (male more than female), ARKO(ACTB-Cre) and Hep-ARKO mice of both sexes had similar delayed tumor occurrence and decreased tumor foci than their Wt littermates. As testosterone levels in Hep-ARKO mice were comparable to the corresponding Wt mice in both genders, the Learning AR roles in cancers via ARKO mice C Chang et al observed difference in tumor incidence was due to the AR status rather than the serum testosterone levels, which are low in ARKO(ACTB-Cre) mice. Liver tumors from male ARKO(ACTB-Cre) and Hep-ARKO mice exhibited lower proliferation index and higher apoptosis index than tumors from Wt males. In human HCC cells, AR knock-in resulted in increased cell proliferation, decreased cell apoptosis and increased anchorage-independent cell growth in vitro. In contrast, AR knock-down with AR-siRNA or ASC-J9 suppressed cell proliferation and enhanced cell apoptosis. Loss of the AR in the liver also resulted in less oxidative stress and decreased DNA damage with increased expression of p53 and its downstream target gene, p21, in the tumors of Hep-ARKO mice compared with tumors of Wt littermates. 95 These results suggested that the AR functions to promote proliferation and suppresses apoptosis of tumor cells in HCC. In addition, the AR might promote hepatocarcinogenesis through increase of oxidative stress and DNA damage, possibly via suppression of p53-mediated DNA damage sensing and repair system as well as p53-mediated apoptosis. It was proposed that the AR may be a new therapeutic target of HCC as injection of ASC-J9 suppressed tumor growth in nude mice inoculated with primary liver tumor cells. 95 Jie et al. 96 reported that in various human HCC cells, DHTstimulated cell proliferation and suppressed apoptosis in an ARdependent manner. The effect of DHT on HCC cell proliferation and apoptosis was mediated through the AR-stimulated expression of parentally expressed gene 10 (PEG10), which regulates the expression of human telomerase reverse transcriptase. The growth of subcutaneous xenografts of various HCC cells were also found to be mediated by the AR and PEG10. These observations appear to corroborate those found in Hep-ARKO mice suggesting that the AR has an important role in hepatocellular carcinogenesis by promoting cell proliferation and suppressing cell apoptosis.
Loss of hepatic AR promotes HCC cell invasion
The above study of DEN-induced HCC was made in Hep-ARKO mice at ages up to 36 weeks old. Recently, Ma et al. 95 have observed that when DEN-treated male Hep-ARKO mice were grown to beyond 40 weeks old, the size of their HCC tumors were comparable to tumors of their Wt littermates. The primary tumors from Hep-ARKO mice appeared less differentiated and exhibited more malignant features than tumors of Wt littermates. At 60 weeks, HCC in Hep-ARKO mice metastasized to the lung with greater incidence (66.7%) than in their Wt littermates (14.3%). Consequently, male Hep-ARKO mice had poorer cancer survival rates than their Wt littermates. Female Hep-ARKO mice exhibited a similar trend of cancer survival in comparison with female Wt mice. As the HCC progressed from 30 to 60 weeks, the elevated levels of p53 expression in Hep-ARKO tumors relative to Wt tumors were gradually diminished. In contrast, p38 phosphorylation/activation, which is linked to HCC progression, 97 was found increased in Hep-ARKO tumors compared with Wt tumors. Transfection of a functional AR in primary Hep-ARKO cells resulted in decreased p38 phosphorylation/activation. Activation of p38 in primary tumor cells of Wt mice with anisomycin resulted in suppression of cell anoikis, a p38-modulated suspension cell death 98 well-linked to HCC metastasis. 99 Primary HCC cells from Wt mice had higher cell anoikis than cells from Hep-ARKO mice. Moreover, knock-down of the AR in primary HCC cells of Wt mice with AR-siRNA resulted in suppression of cell anoikis, whereas knock-in of the AR in primary HCC cells from Hep-ARKO mice resulted in increased cell anoikis. These observations suggested that p38 phosphorylation was increased in HCC progression and the loss of hepatic AR enhanced p38 phosphorylation that led to the suppression of cell anoikis, which may then promote HCC metastasis. 99 AR knock-in and knock-down studies in human HCC cells in vitro also yielded results indicating that the AR enhances cell anoikis in a p38-dependent manner. These treatments of human HCC cells and primary HCC cells from Hep-ARKO and Wt mice indicated that the AR-suppressed HCC cell invasion could also function through suppressing the expression levels of nuclear factor-kB and its target matrix metalloproteinase-9.
Loss of hepatic AR-suppressed HBV-induced HCC development A transgenic mouse model carrying hepatitis B virus gene (HBV mice) has been generated and shown to develop HCC on treatment with DEN at a low dose that does not cause cancer in Wt mice, 100 suggesting HBV-mediated hepatocarcinogenesis. To study the AR role(s) in hepatocarcinogenesis in HBV mice, Wu et al. 101 have generated a Hep-ARKO model of HBV mice (Hep-ARKO/HBV mice), and found that development of premalignant lesions, HCC incidence, tumor volume and number of tumor foci in Hep-ARKO/HBV mice were decreased significantly in comparison with HBV mice. Further analyses indicated that AR loss in hepatocytes resulted in decreased HBV DNA and RNA transcription levels in the liver, and the AR was able to bind to the HBV core promoter to promote its activity. The effect of the AR on the HBV core promoter activity was further enhanced by the addition of HBV X protein, an observation in good agreement with previous reports that HBV X protein enhanced AR transactivation. [100] [101] [102] In Hep-G2 cells, co-transfection of the AR and HBV resulted in enhancement of AR transactivation, increasing the tumorigenecity, and decreased apoptosis. These observations suggest that the AR promotes HBV-mediated hepatocarcinogenesis via a positive feedback mechanism, a notion supported by the observation that tumors of Hep-ARKO/ HBV mice contained fewer proliferating cells than tumors of HBV mice. As tumors from Hep-ARKO/HBV mice, in comparison with HBV mice, displayed reduced expression of various HCC tumorigenecity-related oncogenes including c-Fos and cMyc that are linked to HBV-mediated carcinogenesis, 103, 104 Wu et al.
101
proposed that the AR enhances HBV-mediated hepatocarcinogenesis by regulating the expression of these genes. Treatment of HBV mice with ASC-J9 also resulted in fewer tumor foci and reduced tumor mass compared with controls indicating that the AR is a potential target for treating HBV-mediated HCC. The above studies strongly suggest that hepatocytic AR has dual yet opposite roles during carcinogenesis and metastasis of HCC. During the early stage of hepatocarcinogenesis, the AR appears to promote HCC tumorigenesis and cell proliferation. However, during the later stages of HCC progression, the AR functions as a suppressor of HCC metastasis. The dual roles of the AR appear to explain the previous failures of treating HCC patients with ADT. The finding that the hepatic AR has a suppressor role in HCC metastasis is also in good accord with a previous clinical study demonstrating that poorly differentiated hepatocytes in high-grade HCC tumors exhibited reduced AR expression. Therefore, because of the differential roles of the AR during HCC carcinogenesis and metastasis, Tavian et al. 105 proposed that patients with early stage HCC can be treated by targeting the AR through the use of agents such as ASC-J9 to promote AR degradation. In contrast, treatment of late HCC metastasis stage patients with an inhibitor of p38 in combination with an inhibitor of nuclear factor-kB or matrix metalloproteinase-9 should provide a better treatment regimen to combat liver cancer.
CONCLUSION AND FUTURE PROSPECTS
Using various ARKO mouse models to knockout AR in individual cells to study AR roles in various tumors led to very interesting yet distinct conclusions (Figure 1 ): while the AR functions with positive roles to promote tumorigenesis in all tumors studied so far, including the prostate, liver, bladder, kidney, breast and lung cancers, the AR functions differentially in either suppressing or promoting metastases in these tumors. Thus, the AR functions as a suppressor in prostate and liver metastases and knockout of the AR in PCa epithelial cells or liver cancer hepatocytes led to decreased survival rate and mice died earlier compared with their control littermates. In contrast, the AR functions as stimulator in bladder, kidney and lung metastases since knockout of the AR in BCa urothelial cells, RCC epithelial cells and lung cancer cells led to decrease in metastasis as compared with their controls. Molecular mechanism dissection found the AR might need to go through different signaling pathways to influence metastasis and affect tumor growth. 10, 43, 95 However, why the AR functions differentially in metastases from different tumors remains to be elucidated. This explains why we observe failure in universal targeting of the androgen/AR signaling in some tumor cases and it becomes necessary to consider these cell type-and tissue-specific AR roles in developing therapeutics to cure each cancer. In some cancers, such as UUTUC and RCC, which showed gender difference with clear AR roles, further studies using the cell type-or tissue-specific ARKO mouse models in these tumors will further clarify the AR in vivo roles and help to develop effective therapeutic approaches to battle these hormone-related cancers more effectively. It was interesting to observe that ASC-J9, which is capable of promoting AR degradation, produced antitumor effects similar to those observed in various ARKO mouse cancer models. However, it remains to be elucidated whether or not this AR degradation enhancer may also go through AR-independent signaling to suppress tumor progression.
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